PRINTER'S NO. 301
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE BILL
No.
124
Session of
2017
INTRODUCED BY KAUFER, READSHAW, FEE, DRISCOLL, TAYLOR, MURT,
MILLARD, RADER, B. MILLER, PICKETT, DAVIS, MULLERY, McNEILL,
WATSON, BOBACK, D. MILLER, SIMMONS, SAYLOR, CUTLER AND COOK,
FEBRUARY 3, 2017
REFERRED TO COMMITTEE ON PROFESSIONAL LICENSURE,
FEBRUARY 3, 2017
AN ACT
Amending the act of December 20, 1985 (P.L.457, No.112),
entitled "An act relating to the right to practice medicine
and surgery and the right to practice medically related acts;
reestablishing the State Board of Medical Education and
Licensure as the State Board of Medicine and providing for
its composition, powers and duties; providing for the
issuance of licenses and certificates and the suspension and
revocation of licenses and certificates; provided penalties;
and making repeals," providing for provision of buprenorphine
and legend drugs and further providing for reasons for
refusal, revocation, suspension or other corrective actions
against a licensee or certificate holder.
The General Assembly of the Commonwealth of Pennsylvania
hereby enacts as follows:
Section 1. The act of December 20, 1985 (P.L.457, No.112),
known as the Medical Practice Act of 1985, is amended by adding
a section to read:
Section 36.3. Provision of buprenorphine and legend drugs.
(a) Duty.--The board shall promulgate guidelines that
restrict the circumstances under which buprenorphine may be
administered to a patient for the purpose of treating drug
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
dependence or addiction. The promulgated guidelines shall
require that the provision of buprenorphine may only occur in
conjunction with an opioid treatment program that meets all of
the following:
(1) Is the subject of a current and valid certification
from the Substance Abuse and Mental Health Services
Administration of the United States Department of Health and
Human Services.
(2) Is comprehensive and includes counseling and
behavioral therapy.
(b) Legend drugs.--The board may adopt guidelines that
establish standards and procedures for prescribing a legend drug
to treat opioid dependence or addiction. The board may limit the
application of the guidelines to treatment provided through an
office-based practice or other practice type or location
specified by the board.
Section 2. Section 41 of the act is amended by adding a
paragraph to read:
Section 41. Reasons for refusal, revocation, suspension or
other corrective actions against a licensee or
certificate holder.
The board shall have authority to impose disciplinary or
corrective measures on a board-regulated practitioner for any or
all of the following reasons:
* * *
(12) Violating section 36.3(a). The board shall
promulgate guidelines providing for specific periods of
license suspension or revocation for dispensing, injecting,
implanting or prescribing buprenorphine in violation of
section 36.3.
20170HB0124PN0301 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Section 3. This act shall take effect in 60 days.
20170HB0124PN0301 - 3 -
1